Innovent Announces Picankibart (IBI112) Achieved Primary End

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | Taiwan News

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | Taiwan News
taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.

Related Keywords

Shanghai , China , Yulin Shi , Shaanxi , Suzhou , Jiangsu , Chinese , Eli Lilly , Adimab Incyte , Innovent Biologics , Md Anderson Cancer Center , Linkedin , National Medical Product Administration , Prnewswire Innovent Biologics Inc , Clinical Development Of Innovent , Drug Evaluation , Psoriasis Area , Severity Index , Global Assessment , Dermatology Life Quality Index , Shanghai Skin Disease Hospital , Lei Qian , Vice President , Clinical Development ,